Related Experiment Video
Updated: Jan 24, 2026
11:19
Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
18.5K
Abstract:
According to preliminary data from the phase I/Ib STARTRK-NG trial, the investigational multikinase inhibitor entrectinib showed efficacy in children and adolescents with CNS and other tumor types harboring NTRK1/2/3, ROS1, or ALK fusions. Durable responses were seen even in CNS tumors such as high-grade glioma.
Insights
Entrectinib shows promise in treating pediatric cancers with specific genetic fusions, including brain tumors. This investigational drug achieved durable responses in children and adolescents, highlighting its potential in oncology.
Area of Science:
- Pediatric Oncology
- Molecular Targeted Therapy
- Cancer Genomics
Background:
- The STARTRK-NG trial is evaluating entrectinib, a multikinase inhibitor, in pediatric and adolescent patients.
- The study focuses on tumors with specific genetic alterations: NTRK1/2/3, ROS1, or ALK fusions.
- Central nervous system (CNS) tumors are included in the trial's scope.
Discussion:
- Preliminary data indicate entrectinib's efficacy across various tumor types in young patients.
- The drug demonstrated durable responses, suggesting sustained therapeutic benefit.
- Particular attention is given to efficacy in challenging CNS tumors like high-grade glioma.
Key Insights:
- Entrectinib exhibits significant anti-tumor activity in pediatric and adolescent populations.
- The presence of NTRK, ROS1, or ALK fusions is a key predictive biomarker for response.
- Durable responses, even in CNS malignancies, underscore the drug's potential.
Outlook:
- Further investigation is warranted to confirm these findings in larger pediatric cohorts.
- Entrectinib may offer a new targeted treatment option for pediatric cancers with specific fusions.
- The trial's outcomes could influence future treatment strategies for pediatric brain and other tumors.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
00:52Potential Energy
42.4K
The energy stored by a structure and location of matter in space is called potential energy. For instance, raising a kettlebell changes its spatial location and increases its potential energy. Similarly, a stretched rubber band contains potential energy which, under certain conditions, can be converted into other forms of energy, such as kinetic energy.
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
42.4K
01:09Potential Energy
984
A conservative force, such as a gravitational or elastic force, gives the body the capacity to do work. This capacity, measured as the potential energy, depends on the body's location or “position” relative to a fixed reference position or datum. The gravitational potential energy is considered zero at the reference point. Suppose a body is located at some vertical distance above a fixed horizontal reference or datum. In that case, the weight of the body has positive gravitational potential...
984
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
276
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
276
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
200
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
200
03:02Standard Electrode Potentials
50.0K
On comparing the reactivity of silver and lead, it is observed that the two ionic species, Ag+ (aq) and Pb2+ (aq), show a difference in their redox reactivity towards copper: the silver ion undergoes spontaneous reduction, while the lead ion does not. This relative redox activity can be easily quantified in electrochemical cells by a property called cell potential. This property is commonly known as cell voltage in electrochemistry, and it is a measure of the energy which accompanies the charge...
50.0K